In a phase 1 study, ELI-002 2P improved relapse-free survival in pancreatic and colorectal cancer, with stronger benefit in ...

The ELI-002 2P vaccine is an "off-the-shelf" therapy targeting KRAS mutations common in pancreatic and colorectal cancers.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

A new cancer vaccine targeting KRAS gene mutations shows promise in preventing pancreatic and colorectal cancer recurrence in ...

Bayer has teamed up with Kumquat Biosciences for a juicy opportunity, committing up to $1.3 billion for the global license to ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...

Researchers found that the vaccine, named ELI-002 2P, could trigger lasting immune responses and may help prevent or delay ...

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.

New clinical data reveals promising efficacy of VS-7375, a KRAS G12D inhibitor, in advanced lung cancer, highlighting its ...

Researchers recently discovered that an experimental cancer vaccine offers "a promising approach" to preventing cancers from ...

Bayer partners with Kumquat Biosciences to advance a promising Kras G12D cancer treatment, aiming to address critical unmet ...

A novel cancer vaccine that stimulates the immune system to target one of the most common cancer-driving mutations has shown ...